202 related articles for article (PubMed ID: 21714698)
1. Malignant pheochromocytoma and paraganglioma: three cases illustrating the use of molecular targeted diagnostics and therapy and possible role of new drugs.
Zukauskaite R; Hjorthgau K; Poulsen PL; Baerentzen S; Ladekarl M
Acta Oncol; 2011 Nov; 50(8):1255-9. PubMed ID: 21714698
[No Abstract] [Full Text] [Related]
2. Effects and safety of ¹³¹I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: results from a multicenter observational registry.
Yoshinaga K; Oriuchi N; Wakabayashi H; Tomiyama Y; Jinguji M; Higuchi T; Kayano D; Fukuoka M; Inaki A; Toratani A; Okamoto S; Shiga T; Ito YM; Nakajo M; Nakajo M; Kinuya S; ; ;
Endocr J; 2014; 61(12):1171-80. PubMed ID: 25214026
[TBL] [Abstract][Full Text] [Related]
3. Molecular imaging and theranostic approaches in pheochromocytoma and paraganglioma.
Taïeb D; Pacak K
Cell Tissue Res; 2018 May; 372(2):393-401. PubMed ID: 29450723
[TBL] [Abstract][Full Text] [Related]
4. Treatment of malignant phaeochromocytoma, paraganglioma and carcinoid tumours with 131I-metaiodobenzylguanidine.
Bomanji J; Britton KE; Ur E; Hawkins L; Grossman AB; Besser GM
Nucl Med Commun; 1993 Oct; 14(10):856-61. PubMed ID: 8233228
[TBL] [Abstract][Full Text] [Related]
5. Iodine-131 metaiodobenzylguanidine (I-131 MIBG) diagnosis and therapy of pheochromocytoma and paraganglioma: current problems, critical issues and presentation of a sample case.
Castellani MR; Aktolun C; Buzzoni R; Seregni E; Chiesa C; Maccauro M; Aliberti GL; Vellani C; Lorenzoni A; Bombardieri E
Q J Nucl Med Mol Imaging; 2013 Jun; 57(2):146-52. PubMed ID: 23822990
[TBL] [Abstract][Full Text] [Related]
6. Functional Imaging Evidence of Tumor Response to High-Specific-Activity 131 I-MIBG Therapy in an 84-Year-Old Patient With Metastatic Pheochromocytoma/Paraganglioma.
Jimenez C; Lu Y
Clin Nucl Med; 2023 May; 48(5):426-427. PubMed ID: 36728291
[TBL] [Abstract][Full Text] [Related]
7. High-Specific-Activity-
Jha A; Taïeb D; Carrasquillo JA; Pryma DA; Patel M; Millo C; de Herder WW; Del Rivero J; Crona J; Shulkin BL; Virgolini I; Chen AP; Mittal BR; Basu S; Dillon JS; Hope TA; Mari Aparici C; Iagaru AH; Hicks RJ; Avram AM; Strosberg JR; Civelek AC; Lin FI; Pandit-Taskar N; Pacak K
Clin Cancer Res; 2021 Jun; 27(11):2989-2995. PubMed ID: 33685867
[TBL] [Abstract][Full Text] [Related]
8. Malignant pheochromocytoma and paraganglioma: management options.
Corssmit EPM; Snel M; Kapiteijn E
Curr Opin Oncol; 2020 Jan; 32(1):20-26. PubMed ID: 31599769
[TBL] [Abstract][Full Text] [Related]
9. Phaeochromocytomas and paragangliomas: A difference in disease behaviour and clinical outcomes.
Ezzat Abdel-Aziz T; Prete F; Conway G; Gaze M; Bomanji J; Bouloux P; Khoo B; Caplin M; Mushtaq I; Smart J; Kurzawinski TR
J Surg Oncol; 2015 Oct; 112(5):486-91. PubMed ID: 26337393
[TBL] [Abstract][Full Text] [Related]
10. Role of imaging test with radionuclides in the diagnosis and treatment of pheochromocytomas and paragangliomas.
Araujo-Castro M; Pascual-Corrales E; Alonso-Gordoa T; Molina-Cerrillo J; Martínez Lorca A
Endocrinol Diabetes Nutr (Engl Ed); 2022 Oct; 69(8):614-628. PubMed ID: 36402734
[TBL] [Abstract][Full Text] [Related]
11. From Diagnosis to Therapy-PET Imaging for Pheochromocytomas and Paragangliomas.
Patel HV; Srivastava A; Becker MD; Beninato T; Laird AM; Singer EA
Curr Urol Rep; 2021 Jan; 22(1):2. PubMed ID: 33403502
[TBL] [Abstract][Full Text] [Related]
12. Phaeochromocytomas and functional paragangliomas: clinical management.
Plouin PF; Amar L; Lepoutre C
Best Pract Res Clin Endocrinol Metab; 2010 Dec; 24(6):933-41. PubMed ID: 21115162
[TBL] [Abstract][Full Text] [Related]
13. Functional imaging for pheochromocytoma-paraganglioma: a step closer to understanding its place in clinical practice.
Jimenez C; Waguespack SG
Endocrine; 2015 Sep; 50(1):6-8. PubMed ID: 26113425
[No Abstract] [Full Text] [Related]
14. I-131 metaiodobenzylguanidine therapy is a significant treatment option for pheochromocytoma and paraganglioma.
Zhang X; Wakabayashi H; Kayano D; Inaki A; Kinuya S
Nuklearmedizin; 2022 Jun; 61(3):231-239. PubMed ID: 35668668
[TBL] [Abstract][Full Text] [Related]
15. New imaging approaches to phaeochromocytomas and paragangliomas.
Dullaart RP; van der Horst-Schrivers AN; Koopmans KP
Clin Endocrinol (Oxf); 2010 Apr; 72(4):568-9; author reply 569. PubMed ID: 19769625
[No Abstract] [Full Text] [Related]
16. Metastatic pheochromocytoma and paraganglioma: focus on therapeutics.
Plouin PF; Fitzgerald P; Rich T; Ayala-Ramirez M; Perrier ND; Baudin E; Jimenez C
Horm Metab Res; 2012 May; 44(5):390-9. PubMed ID: 22314389
[TBL] [Abstract][Full Text] [Related]
17. Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups.
Taïeb D; Jha A; Treglia G; Pacak K
Endocr Relat Cancer; 2019 Nov; 26(11):R627-R652. PubMed ID: 31561209
[TBL] [Abstract][Full Text] [Related]
18. Low-dose (123)I-metaiodobenzylguanidine diagnostic scan is inferior to (131)I-metaiodobenzylguanidine posttreatment scan in detection of malignant pheochromocytoma and paraganglioma.
Kayano D; Taki J; Fukuoka M; Wakabayashi H; Inaki A; Nakamura A; Kinuya S
Nucl Med Commun; 2011 Oct; 32(10):941-6. PubMed ID: 21876405
[TBL] [Abstract][Full Text] [Related]
19. Pheochromocytoma and paraganglioma.
Meyer-Rochow GY; Sidhu SB
Cancer Treat Res; 2010; 153():135-62. PubMed ID: 19957224
[No Abstract] [Full Text] [Related]
20. A rare association of pheochromocytoma and thoracic paraganglioma: utility of 2D contrast enhanced echocardiography.
Delgado V; Vidal B; Sitges M; Azqueta M; Pare C
Int J Cardiol; 2007 Apr; 117(2):e66-7. PubMed ID: 17320209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]